NCT05963347招募中2 期
A Phase 2 Study to Investigate the Safety, Tolerability and Anti-tumor Activity of Golidocitinib in Combination With CHOP as the Front-line Treatment for Participants With Peripheral T-cell Lymphomas (PTCL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
研究概览
简要总结
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must sign an informed consent form prior to trial-specific procedures, sampling, and analysis.
- •Participants must be at least 18 years of age (inclusive) at the time of signing the informed consent form.
- •The participant has an ECOG performance status of 0 to 2 and has not deteriorated in the past 2 weeks.
- •Life expectancy ≥ 3 months.
- •Histologically confirmed diagnosis of PTCL and no prior systemic anti-lymphoma therapy; and assessed by a local pathologist according to the 2016 revised World Health Organization Classification of Lymphoid Tumors (Swerdlow SH et al., 2017) as the following subtypes:
- •peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS)
- •angioimmunoblastic T cell lymphoma (AITL)
- •follicular T-cell lymphoma (FTCL)
- •nodular PTCL with follicular helper T-cell phenotype (nodular PTCL with TFH phenotype)
- •ALK- anaplastic large cell lymphoma (ALK- ALCL)
- •ALK+ anaplastic large cell lymphoma (ALK + ALCL)
- •enteropathy-associated T-cell lymphoma (EATL)
- •monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)
- •hepatosplenic T-cell lymphoma (HSTCL)
- •subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
- •Adequate bone marrow reserve and organ system function reserve
- •Left ventricular ejection fraction (LVEF) ≥ 50% as assessed by ECHO.
- •Participants should be able and willing to comply with the study protocol requirement.
- •Adequate birth control measures should be taken during study treatment and the corresponding washout period.
排除标准
- •Received any of the following interventions:
- •Prior therapy for PTCL prior to enrollment, except short-term corticosteroids (duration ≤ 7 days, equivalent prednisone dose ≤ 15 mg/day).
- •Prior radiation therapy for PTCL except local therapy for individual areas.
- •Currently receiving other systemic antineoplastic or investigational therapy.
- •Participants who have received more than 200 mg/m2 doxorubicin or other equivalent doses of anthracycline/anthraquinone (e.g., epirubicin, daunorubicin, mitoxantrone, etc.) cumulatively.
- •Major surgical procedures (excluding routine lymphoma care programs such as vascular access placement, biopsy, etc.) or significant trauma within 4 weeks prior to the first dose of study treatment, or anticipation of the need for major surgery during the study.
- •Prior treatment with JAK or STAT3 inhibitors following diagnosis of PTCL.
- •Live vaccine within 28 days prior to enrollment.
- •Participants currently receiving (or unable to discontinue for at least 1 week prior to first dose) vitamin K antagonists, antiplatelets, or anticoagulants.
- •Participants currently receiving (or unable to discontinue for at least 1 week prior to receiving the first dose) medications or herbal supplements known to be highly potent inhibitors or inducers of CYP3A or sensitive substrates of BCRP or P-gp with a narrow therapeutic index (see Section 6.8).
- •Participants with clinical manifestations or imaging findings suggesting central nervous system or leptomeningeal lymphoma.
- •Participants with severe lung dysfunction, pneumonitis, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any prior history of clinically active interstitial lung disease.
- •Participants with a condition that requires treatment with immunosuppressants, biologics, or nonsteroidal anti-inflammatory drugs (NSAIDs).
- •Participants with active infections
- •Participants with significant cardiac disorder
- •Other malignancies within 3 years before enrollment. However, malignancies, such as uterine and cervical carcinoma in situ, basal or squamous cell carcinoma, and non-melanotic skin cancer, which have been clinically cured after evaluation, may be considered for inclusion after evaluation.
- •Refractory nausea or vomiting that cannot be controlled by supportive therapy, chronic gastrointestinal disease, inability to swallow pharmaceutical agents or previous major bowel resection may affect the adequate absorption of golidocitinib.
- •Female participants who are lactating.
- •Participants with a history of hypersensitivity against the active ingredients or excipients of golidocitinib or against similar chemical structures or drugs of the same class. Contraindication to any agent in the CHOP chemotherapy regimen.
- •Participants with any severe or poorly controlled systemic disease, such as poorly controlled hypertension or active bleeding constitution, as judged by the investigator or other evidence.
- •Participants with an intercurrent illness that, in the opinion of the investigator, may jeopardize compliance with the protocol, including any significant medical condition, laboratory abnormality, or psychiatric disorder.
- •Participants with psychological, familial, social, or geographical conditions that preclude compliance with the program. Any condition that would confound the ability to interpret study data.
- •Participating in study planning and implementation.
研究组 & 干预措施
Go-CHOP
Experimental
Golidocitinib in combination with CHOP
干预措施: Golidocitinib (Drug)
Go-CHOP
Experimental
Golidocitinib in combination with CHOP
干预措施: CHOP Regimen (Drug)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
时间窗: From first dose till 28 days post the last dose
TEAE, lab test
次要结局
- Complete Response Rate(From date of enrollment (first dose) until the end of induction therapy completed (~ 18 weeks))
- Objective Response Rate(From date of enrollment (first dose) until the end of induction therapy completed (~ 18 weeks))
- Duration of Response(from first documented response till disease progression or death of any reason (up to 2 years))
- Progression Free Survival(From date of enrollment (first dose) until documented disease progression or death of any reason (up 2 year))
研究者
KeshuZhou
Professor
Henan Cancer Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)Non-Small-Cell Lung CancerNCT06198907Cancer Institute and Hospital, Chinese Academy of Medical Sciences69
终止
1 期
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid TumorsSolid TumorsColorectal CancerNCT05731947Syndax Pharmaceuticals41
已完成
1 期
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without TislelizumabGastroesophageal Junction CancerBreast CancerGastric CancerNCT04276493BeiGene71
已完成
2 期
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHLDiffuse Large B-Cell LymphomaB-cell Non-Hodgkin's LymphomaNCT02564744Debiopharm International SA100
已完成
2 期
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT00874107HiberCell, Inc.90